ImpediMed Limited
ImpediMed Limited, a medical technology company, develops, manufactures, and sells bioimpedance spectroscopy (BIS) technology medical devices and software services in Australia, Europe, the United States, and internationally. The company offers SOZO, a noninvasive BIS device for the clinical assessment of lymphedema, which uses bioimpedance measurements to assess fluid levels and tissue compositi… Read more
ImpediMed Limited (IPDQF) - Total Assets
Latest total assets as of June 2025: $41.66 Million USD
Based on the latest financial reports, ImpediMed Limited (IPDQF) holds total assets worth $41.66 Million USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
ImpediMed Limited - Total Assets Trend (2007–2025)
This chart illustrates how ImpediMed Limited’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
ImpediMed Limited - Asset Composition Analysis
Current Asset Composition (June 2025)
ImpediMed Limited's total assets of $41.66 Million consist of 66.0% current assets and 34.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 53.3% |
| Accounts Receivable | $2.96 Million | 7.1% |
| Inventory | $861.00K | 2.1% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $10.19 Million | 24.5% |
| Goodwill | $2.78 Million | 6.7% |
Asset Composition Trend (2007–2025)
This chart illustrates how ImpediMed Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ImpediMed Limited's current assets represent 66.0% of total assets in 2025, a decrease from 85.2% in 2007.
- Cash Position: Cash and equivalents constituted 53.3% of total assets in 2025, down from 74.7% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 30.0% of total assets, an increase from 13.0% in 2007.
- Asset Diversification: The largest asset category is intangible assets at 24.5% of total assets.
ImpediMed Limited Competitors by Total Assets
Key competitors of ImpediMed Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Cheelcare Inc.
V:CHER
|
Canada | CA$4.27 Million |
|
FluroTech Ltd
OTCQB:FLURF
|
USA | $282.20K |
|
DRGEM Corporation
KQ:263690
|
Korea | ₩119.28 Billion |
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022
|
China | CN¥5.17 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.67 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
China | CN¥6.10 Billion |
|
Shinhung
KO:004080
|
Korea | ₩153.50 Billion |
ImpediMed Limited - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - ImpediMed Limited generates 0.31x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - ImpediMed Limited is currently not profitable relative to its asset base.
ImpediMed Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.86 | 6.33 | 4.98 |
| Quick Ratio | 4.71 | 6.16 | 4.81 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $21.85 Million | $ 24.80 Million | $ 20.34 Million |
ImpediMed Limited - Advanced Valuation Insights
This section examines the relationship between ImpediMed Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.97 |
| Latest Market Cap to Assets Ratio | 0.86 |
| Asset Growth Rate (YoY) | -11.3% |
| Total Assets | $41.66 Million |
| Market Capitalization | $36.00 Million USD |
Valuation Analysis
Near Book Valuation: The market values ImpediMed Limited's assets close to their book value ( 0.86x), suggesting investors view the company's assets at approximately fair value.
Significant Asset Reduction: ImpediMed Limited's assets decreased by 11.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for ImpediMed Limited (2007–2025)
The table below shows the annual total assets of ImpediMed Limited from 2007 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | $41.66 Million | -11.34% |
| 2024-06-30 | $46.99 Million | -31.64% |
| 2023-06-30 | $68.74 Million | +17.10% |
| 2022-06-30 | $58.70 Million | +71.61% |
| 2021-06-30 | $34.20 Million | +3.45% |
| 2020-06-30 | $33.06 Million | +46.42% |
| 2019-06-30 | $22.58 Million | -45.94% |
| 2018-06-30 | $41.77 Million | -35.09% |
| 2017-06-30 | $64.34 Million | -28.96% |
| 2016-06-30 | $90.57 Million | +138.86% |
| 2015-06-30 | $37.92 Million | +153.49% |
| 2014-06-30 | $14.96 Million | +26.08% |
| 2013-06-30 | $11.86 Million | -39.51% |
| 2012-06-30 | $19.61 Million | -13.99% |
| 2011-06-30 | $22.80 Million | -8.45% |
| 2010-06-30 | $24.91 Million | +90.18% |
| 2009-06-30 | $13.10 Million | -9.76% |
| 2008-06-30 | $14.52 Million | -33.38% |
| 2007-06-30 | $21.79 Million | -- |